Mazyar Shadman

8.5k total citations · 2 hit papers
221 papers, 2.3k citations indexed

About

Mazyar Shadman is a scholar working on Oncology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Mazyar Shadman has authored 221 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Oncology, 92 papers in Genetics and 91 papers in Pathology and Forensic Medicine. Recurrent topics in Mazyar Shadman's work include Chronic Lymphocytic Leukemia Research (91 papers), Lymphoma Diagnosis and Treatment (88 papers) and CAR-T cell therapy research (87 papers). Mazyar Shadman is often cited by papers focused on Chronic Lymphocytic Leukemia Research (91 papers), Lymphoma Diagnosis and Treatment (88 papers) and CAR-T cell therapy research (87 papers). Mazyar Shadman collaborates with scholars based in United States, Australia and South Africa. Mazyar Shadman's co-authors include Ajay K. Gopal, David G. Maloney, Victor A. Chow, Cameron J. Turtle, Brian G. Till, Jordan Gauthier, Bahman Roudsari, Alexandre V. Hirayama, Ryan D. Cassaday and Stephen J. Schuster and has published in prestigious journals such as JAMA, Circulation and Journal of Clinical Oncology.

In The Last Decade

Mazyar Shadman

185 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

2020 227 citations Jordan Gauthier, Alexandre V. Hirayama et al. Blood profile →
Diagnosis and Treatment of Chronic Lymphocytic Leukemia

2023 97 citations Mazyar Shadman profile →

Peers

Countries citing papers authored by Mazyar Shadman

Since Specialization

Citations

This map shows the geographic impact of Mazyar Shadman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mazyar Shadman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mazyar Shadman more than expected).

Fields of papers citing papers by Mazyar Shadman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mazyar Shadman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mazyar Shadman. The network helps show where Mazyar Shadman may publish in the future.

Co-authorship network of co-authors of Mazyar Shadman

This figure shows the co-authorship network connecting the top 25 collaborators of Mazyar Shadman. A scholar is included among the top collaborators of Mazyar Shadman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mazyar Shadman. Mazyar Shadman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Distinct Patterns of Pathogen-Specific and Non-Specific Immune Reconstitution after CD19/20- Versus BCMA-Targeted CAR-T Cell Therapy 2025 ·Transplantation and Cellular Therapy ·Elizabeth M. Krantz, (unknown), (unknown), Julián B. Muñoz, (unknown), (unknown), (unknown), Andrew J. Cowan, Damian J. Green, Jordan Gauthier, Rebecca Gardner, Mazyar Shadman, Jim Boonyaratanakornkit, Cameron J. Turtle, Joshua A. Hill	0
2	Real-world treatment patterns and clinical outcomes among patients with diffuse large B-cell lymphoma in a US healthcare claims database 2025 ·Blood Cancer Journal ·Mazyar Shadman, (unknown), (unknown), Chang Xu, Pei‐Chao Lin, (unknown), Xiaoxiao Lu	0
3	Impact of immunophenotype on clinical disease characteristics and outcomes in T‐cell prolymphocytic leukaemia 2025 ·British Journal of Haematology ·Christina Poh, Xueyan Chen, Jenna Voutsinas, Kikkeri N. Naresh, (unknown), Mazyar Shadman, Ryan C. Lynch, Brian G. Till, Chaitra S. Ujjani, Mengyang Di, (unknown), Edus H. Warren, Stephen D. Smith, Qian Wu, Sindhu Cherian, Ajay K. Gopal	0
4	Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas 2025 ·Blood Advances ·Christina Poh, Jenna Voutsinas, Mazyar Shadman, Ryan C. Lynch, Edus H. Warren, (unknown), Brian G. Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D. Smith, Qian Wu, Michi M. Shinohara, Ajay K. Gopal	1
5	Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis 2024 ·Transplantation and Cellular Therapy ·Christina Poh, Victor A. Chow, Ryan C. Lynch, Chaitra S. Ujjani, Edus H. Warren, Mazyar Shadman, Brian G. Till, (unknown), Jordan Gauthier, Alexandre V. Hirayama, Stephen D. Smith, Taranjit S. Gujral, Chihiro Morishima, (unknown), Jenna Voutsinas, (unknown), David G. Maloney, Ajay K. Gopal	0
6	SINGLE-AGENT EPCORITAMAB LEADS TO DEEP RESPONSES IN PATIENTS (PTS) WITH RICHTER’S TRANSFORMATION (RT): PRIMARY RESULTS FROM THE EPCORE CLL-1 TRIAL 2024 ·University of Southern Denmark Research Portal (University of Southern Denmark) ·Arnon P. Kater, Ann Janssens, Herbert Eradat, Fritz Offner, (unknown), Mazyar Shadman, Christian Bjørn Poulsen, Jacob Haaber Christensen, Meghan C. Thompson, (unknown), А. А. Кузнецова, Toshihiko Oki, Rebecca Valentin, Mar Bellido, (unknown)	1
7	Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy 2024 ·Haematologica ·Santiago Mercadal, Kwang Woo Ahn, (unknown), (unknown), Praveen Ramakrishnan Geethakumari, Sanghee Hong, Adriana K. Malone, Hemant S. Murthy, Attaphol Pawarode, Alejandro Sica, Melhem Solh, Celalettin Üstün, Mazyar Shadman, Craig S. Sauter, Mehdi Hamadani, Alex F. Herrera, Catherine J. Lee	3
8	Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up 2024 ·Blood ·Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, (unknown), Edus H. Warren, Mazyar Shadman, Brian G. Till, Chaitra S. Ujjani, Karolyn Morris, Heather Rasmussen, Jenna Voutsinas, Ajay K. Gopal	1
9	Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis (NMA). 2024 ·Journal of Clinical Oncology ·Mazyar Shadman, Jennifer R. Brown, (unknown), (unknown), Heather Burnett, Binod Neupane, Rhys Williams, Nicole Lamanna, Susan O’Brien, Alessandra Tedeschi, Constantine S. Tam	1
10	Epcoritamab Induces Deep Responses in Patients With Richter Transformation (RT): Primary Results From the EPCORE CLL-1 Trial 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Arnon P. Kater, Ann Janssens, Herbert Eradat, Fritz Offner, Jose Sandoval‐Sus, Mazyar Shadman, Christian Bjørn Poulsen, Jacob Haaber Christensen, Meghan C. Thompson, (unknown), А. А. Кузнецова, Toshihiko Oki, Rebecca Valentin, Mar Bellido, (unknown)	2
11	Early prediction of severe ICANS after standard-of-care CD19 CAR T-cell therapy using gradient-boosted classification trees. 2024 ·Journal of Clinical Oncology ·Jennifer J. Huang, Emily C. Liang, (unknown), Andrew J. Portuguese, (unknown), (unknown), (unknown), (unknown), Barbara Pender, Mazyar Shadman, Alexandre V. Hirayama, Brian G. Till, Erik L. Kimble, Lorenzo Iovino, Aude G. Chapuis, Folashade Otegbeye, Ryan D. Cassaday, Filippo Milano, David G. Maloney, Jordan Gauthier	2
12	A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016 2023 ·Hematological Oncology ·Mazyar Shadman, (unknown), Lisa M. Rimsza, John P. Leonard, Mark Kaminski, Catherine Spier, Ajay K. Gopal, Shaker R. Dakhil, Michael LeBlanc, Sonali M. Smith, Jonathan W. Friedberg	1
13	Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies 2023 ·Haematologica ·(unknown), (unknown), Mazyar Shadman, (unknown), (unknown), Jeanne Fredrickson, Brendan F. Kohrn, Chaitra S. Ujjani, (unknown), Brian G. Till, Min Fang, Jerald P. Radich, Ivana Božić, Rosa Ana Risques, Cecilia C.S. Yeung	4
14	Minimal Residual Disease (MRD) Status Predicts Outcomes in Patients with Follicular Lymphoma (FL) Treated with Chemo-Immunotherapy on SWOG S0016 2023 ·Blood ·Alexey V. Danilov, Hongli Li, Mazyar Shadman, Lisa M. Rimsza, Ahmad S. Zebari, Sonali M. Smith, Michael LeBlanc, Jonathan W. Friedberg, Christopher S. Carlson, Joo Y. Song	0
15	Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Matthew J. Matasar, Nancy L. Bartlett, Mazyar Shadman, Lihua E. Budde, Ian W. Flinn, Gareth P. Gregory, Won Seog Kim, Georg Heß, Dima El‐Sharkawi, Catherine Diefenbach, Huang Huang, Iris To, (unknown), (unknown), Antonia Kwan, Sarit Assouline	10
16	2711. Viral encephalitis after chimeric antigen receptor (CAR)-modified T-cell therapy: A Retrospective Cohort Study 2023 ·Open Forum Infectious Diseases ·Eleftheria Kampouri, (unknown), (unknown), (unknown), (unknown), Ryan Basom, Chris Davis, Cameron J. Turtle, Mazyar Shadman, Brian G. Till, Ryan D. Cassaday, Jordan Gauthier, Aude G. Chapuis, David G. Maloney, Elizabeth M. Krantz, Joshua A. Hill	1
17	Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma 2023 ·Blood Advances ·Richard Burack, Hongli Li, Diana G. Adlowitz, (unknown), Lisa M. Rimsza, Mazyar Shadman, Catherine Spier, Mark Kaminski, John P. Leonard, Michael LeBlanc, Sonali M. Smith, Jonathan W. Friedberg	6
18	Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy 2023 ·Bone Marrow Transplantation ·Gèrard Socié, Pere Barba, Arie Barlev, Jaime Sanz, Irene García‐Cadenas, Patrice Chevallier, Franca Fagioli, Norma Guzmán‐Becerra, Deepali Kumar, Per Ljungman, Arnaud Pigneux, Natalia Sadetsky, Lucrecia Yáñez, Mazyar Shadman, Jan Storek, (unknown), (unknown), Mohamad Mohty	9
19	Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma 2022 ·Transplantation and Cellular Therapy ·Pashna N. Munshi, Yue Chen, Kwang Woo Ahn, Farrukh T. Awan, Amanda F. Cashen, Geoffrey Shouse, Mazyar Shadman, Paul Shaughnessy, Joanna Zurko, Frederick L. Locke, Aaron M. Goodman, (unknown), Craig S. Sauter, (unknown), Gabrielle Meyers, Samantha Jaglowski, Alex F. Herrera, Mehdi Hamadani	11
20	In Vivo Localization of 90Y and 177Lu Radioimmunoconjugates Using Cerenkov Luminescence Imaging in a Disseminated Murine Leukemia Model 2014 ·Cancer Research ·(unknown), Aimee L. Kenoyer, Johnnie J. Orozco, (unknown), Mazyar Shadman, Darrell R. Fisher, Damian J. Green, Mark D. Hylarides, Oliver W. Press, D. Scott Wilbur, John M. Pagel	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact